Las Vegas, NV -- (SBWIRE) -- 10/10/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Celsion Corporation (NASDAQ:CLSN), Tianli Agritech, Inc. (NASDAQ:OINK), pSivida Corp.(NASDAQ:PSDV), Atossa Genetics Inc (NASDAQ:ATOS)
Celsion Corporation (NASDAQ:CLSN) managed to keep its fall at -4.07% on below -normal volume of 1.34M shares. The stock settled at $1.18 after floating in a range of $1.15 to $1.24. Its latest price has reached market capitalization of $72.17 million. Its 52-week range has been $0.75to $9.44. Celsion Corporation is an oncology drug development company focused on the development of treatments for those suffering with difficult to treat forms of cancer.
Has CLSN Found The Bottom and Ready To Move Up? Find Out Here
Tianli Agritech, Inc. (NASDAQ:OINK) traded up on a volume of 1.33 million, higher its standard daily volume. Shares have gained 29.13% to $1.64. Over the last twelve months, the stock has gained 12.33% and faced a worst price of $0.50. Tianli Agritech, Inc. (Tianli) is a holding company engaged in the business of research and development, raising, breeding and selling hogs in the People’s Republic of China.
For How Long OINK’s Gloss will Attract Investors? Find out via this report
pSivida Corp.(NASDAQ:PSDV) settled -6.90% lower at $4.72 on above-normal volume of 1.31M shares during the last trading day. The stock has its 12-month high at $5.27 and 52-week low price was $5.60. It traded in a range of $4.50 to $5.27 during the last trading day. pSivida Corp. develops drug delivery products that are administered by implantation, injection or insertion. As of June 30, 2011, the Company is focused on the treatment of chronic eye diseases utilizing its cored technology systems.
Will PSDV Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, Atossa Genetics Inc (NASDAQ:ATOS) was down on high volume, trading at a volume of 1.29M versus its average daily volume of 633,810.00 shares. At $2.12, the stock has attained market capitalization of 33.03 million. Atossa Genetics Inc. is a development-stage healthcare company focused on the prevention of breast cancer through the commercialization of diagnostic tests that can detect precursors to breast cancer, and through the research, development, and ultimate commercialization of treatments for pre-cancerous lesions.
Why Should Investors Buy ATOS After the Recent Fall? Just Go Here and Find Out
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)